CCDC6 and non-small cell lung carcinoma: Our study indicates that the molecular alterations of CCDC6 by impairing the CCDC6 nuclear function may act as ‘BRCA like’ alterations, making cancer cells selective target of PARPi Olaparib which might help to overcome the resistance to the conventional anticancer therapy in NSCLC patients.